

*K*/3  
32  
~~64.~~

A method according to claim ~~60~~<sup>28</sup>, wherein [said composition contains an] the amount of the (+)-enantiomer is [of] 2% w/w.

*K*/3  
33  
~~65.~~

A method according to claim ~~64~~<sup>32</sup>, wherein [said composition contains an] the amount of the (+)-enantiomer is [of] 1% w/w.

*K*/3  
34  
~~66.~~

A method according to claim ~~59~~<sup>27</sup>, wherein [said composition contains an] the amount of the (+)-enantiomer is [of] 2% w/w.

*K*/3  
35  
~~67.~~

A method according to claim ~~66~~<sup>36</sup>, [said composition contains an] the amount of the (+)-enantiomer is [of] 1% w/w.

*K*/4  
49  
~~81.~~

A method for treating a human suffering from HIV infection comprising administering to said human [a pharmaceutical composition comprising]: a compound which is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof, [and another agent having antiviral activity,] wherein the amount of the (+)-enantiomer of said compound or of said pharmaceutically acceptable salt [present in said composition] is no more than 5% w/w, relative to the combined weight of the (-) and (+)-enantiomers thereof, and

another agent having antiviral activity.

*K*/4  
50  
~~82.~~

A method according to claim ~~81~~<sup>49</sup>, wherein said [composition contains] compound is (-)-cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one.

RECEIVED  
MAR 16 2000  
1600 MAIL ROOM

## REMARKS

Upon receipt of the Notice of Allowance, applicants reviewed the claims. It was noted that dependent method claims 33 and 68 clearly recite that the compound and the agent are administered sequentially. Conversely, dependent claims 34 and 69 recite that the compound and agent are administered simultaneously. In addition, claims 78 and 79 recite that the compound and agent are administered in combination.

However, it was also noted that independent method claim 25 referred to a composition comprising the compound (or a pharmaceutically acceptable salt thereof) and the agent. While one of ordinary skill in the art, especially upon reading the dependent claims, would clearly recognize that the compound and agent do not have to be administered in the form of a combined composition, the claims 25, 31, 32, 64-67 and 81-82 are amended above to eliminate the reference to composition.